Psoriasis
Conference Coverage
Reduced-frequency methotrexate monitoring causes no harm
Laboratory blood test results were similar despite moving from once every month to about once every 3 months or about once every 5 months during...
From the Journals
Parents’ autoimmune diseases may affect children’s development
Type 1 diabetes and psoriasis in parents, and rheumatoid arthritis in mothers, are associated with increased risk for autism spectrum disorder and...
Conference Coverage
NB-UVB phototherapy plays a key role in psoriasis treatment, expert says
Home phototherapy booths provide a safe and effective way to use NB-UVB phototherapy while minimizing copays and commuting costs.
From the Journals
Long-term efficacy, safety data for ixekizumab in pediatric psoriasis reported
No new safety findings during weeks 48 to 108 of the trial were reported, including no new cases of inflammatory bowel disease or Candida...
From the Journals
Secukinumab’s antipsoriatic effects confirmed in U.S. patient population
Results from a postmarketing trial conducted solely at U.S. centers found similar, albeit lower, responses to secukinumab 300 mg than was noted in...
Cosmeceutical Critique
Cupping in dermatology
Over the past decade, the popularity of this ancient procedure has been increasing in the United States.
Latest News
International consensus reached on methotrexate dosing for psoriasis
“We hope to raise awareness on the different MTX dosages used in daily practice and the need for a more uniform dosing regimen.”
Conference Coverage
Apremilast has neutral effect on vascular inflammation in psoriasis study
“There has been a keen interest in understanding how psoriasis therapies impact cardiovascular risk.”
Latest News
Study links air pollution to psoriasis flares
The findings underscore the need for clinicians to “consider environmental/external triggers in patients with chronic inflammatory diseases...
From the Journals
CV risk biomarkers tentatively identified in psoriatic disease
Troponin I and NT-proBNP levels were linked to cardiovascular risk independently of the Framingham Risk Score.
From the Journals
Drug survival study looks at what lasts longest in RA, axSpA, PsA, and psoriasis
Survival rates were highest for rituximab in rheumatoid arthritis and golimumab in axial spondyloarthritis in a study of two Danish registries.